David Cappellen (D Cappellen)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Oxide Nanoparticles

Top Venues

Nature communications

JCO precision oncology

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Grégoire Cullot, Julian Boutin, S Fayet, F Prat, J Rosier, David Cappellen, I Lamrissi, Perrine Pennamen, J Bouron, S Amintas, C Thibault, I Moranvillier, E Laharanne, Jean-Philippe Merlio, V Guyonnet-Duperat, J M Blouin, E Richard, S Dabernat, François Moreau-Gaudry, A Bedel
Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9. Nature communications 14 (1) (2023)
David Cappellen, Isabelle Catry-Thomas, Claire Castain, Paulette Bioulac-Sage
Hepatocellular adenoma with a double mutation HNF1A and IDH1 in a patient with Ollier disease. Liver international : official journal of the International Association for the Study of the Liver (2021)
Julian Boutin, J Rosier, David Cappellen, F Prat, J Toutain, Perrine Pennamen, J Bouron, C Rooryck, Jean-Philippe Merlio, I Lamrissi-Garcia, G Cullot, S Amintas, V Guyonnet-Duperat, C Ged, J M Blouin, E Richard, S Dabernat, François Moreau-Gaudry, A Bedel
CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells. Nature communications 12 (1) (2021)
Léa Dousset, Florence Poizeau, Caroline Robert, Sandrine Mansard, Laurent Mortier, Charline Caumont, Émilie Routier, Alain Dupuy, Jacques Rouanet, Maxime Battistella, Anna Greliak, David Cappellen, Marie-Dominique Galibert, Clara Allayous, Alexandra Lespagnol, Emilie Gérard, Inès Kerneuzet, Séverine Roy, Caroline Dutriaux, Jean-Philippe Merlio, Beatrice Vergier, Alexa B Schrock, Jessica Lee, Siraj M Ali, Solène-Florence Kammerer-Jacquet, Celeste Lebbè, Marie Beylot-Barry, Lise Boussemart
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. JCO precision oncology 5 (2021)